Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

Sulkowski, Mark; Gardiner, David; Rodríguez‐Torres, M.; Rajender Reddy, K.; Hassanein, Tarek; M. Jacobson, Ira; Lawitz, Eric; S. Lok, Anna; Hinestrosa, Federico; J. Thuluvath, Paul; Schwartz, Howard; R. Nelson, David; T. Everson, Gregory; Eley, Timothy; Wind‐Rotolo, Megan; Huang, Shu-Pang; Gao, Min; Hernandez, Dennis; McPhee, Fiona; L. Sherman, Diane; Hindes, R.; T. Symonds, William; Pasquinelli, C; M. Grasela, Dennis

doi:10.1056/nejmoa1306218

Public

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

Published in New England Journal of Medicine • Jan 15, 2014

Authors:

Mark Sulkowski

David Gardiner

M. Rodríguez‐Torres

Abstract

BACKGROUND: All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, o...

Subject

Daclatasvir

Sofosbuvir

NS5A

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!